269 related articles for article (PubMed ID: 28511869)
1. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
3. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
5. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
6. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
7. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
8. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
9. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
10. Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers.
Xia Z; Cochrane DR; Tessier-Cloutier B; Leung S; Karnezis AN; Cheng AS; Farnell DA; Magrill J; Schmidt D; Kommoss S; Kommoss FKF; Kommoss F; McAlpine JN; Gilks CB; Koebel M; Rabban JT; Huntsman DG
Hum Pathol; 2019 Oct; 92():39-47. PubMed ID: 31220479
[TBL] [Abstract][Full Text] [Related]
11. TP53 overexpression in recurrent endometrial carcinoma.
Pijnenborg JM; van de Broek L; Dam de Veen GC; Roemen GM; de Haan J; van Engeland M; Voncken JW; Groothuis PG
Gynecol Oncol; 2006 Feb; 100(2):397-404. PubMed ID: 16271749
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
13. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
14. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
15. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
16. p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma.
Burton JL; Stewart RL; Heatley MK; Royds JA; Wells M
Histopathology; 1999 Sep; 35(3):221-9. PubMed ID: 10469214
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
[TBL] [Abstract][Full Text] [Related]
18. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
20. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
